Baseline characteristics of patients achieving a PR-L vs CR/PR at 12 months after ibrutinib therapy
| Characteristic . | CR/PR patients (n = 42) . | PR-L patients (n = 17) . | P value* . |
|---|---|---|---|
| Median age (range) | 66.0 (37-82) | 67.0 (55-75) | |
| Male gender | 30 (71.4%) | 13 (76.5%) | .759 |
| Median baseline WBC (range, 109/L) | 12.3 (1.7-308.1) | 31.6 (3.8-122.0) | .482 |
| Median peak WBC (range, 109/L) | 51.5 (5.2-619.1) | 156.3 (29.1-361.1) | .006 |
| Lymph node size ≥5 cm | 24 (57.1%) | 6 (35.3%) | .158 |
| Lymph node size ≥10 cm | 7 (16.7%) | 2 (11.8%) | 1.000 |
| Rai stage at baseline | |||
| Intermediate (I/II) | 11 (26.2%) | 6 (35.3%) | .753 |
| High (III/IV) | 28 (66.7%) | 11 (64.7) | |
| Unknown | 3 (7.2%) | 0 | |
| Fluorescence in situ hybridization abnormalities | |||
| Trisomy 12 | 6 (14.3) | 0 | .175 |
| Del13q | 15 (35.7%) | 12 (70.6%) | .010 |
| Del11q | 15 (35.7%) | 7 (41.2%) | .444 |
| Del17p | 13 (31.0%) | 3 (17.6%) | .364 |
| IGHV mutated | 5 (11.9%) | 7 (41.2%) | .015 |
| Zap-70 methylated at CpG3 | 11 (26.2%) | 7 (41.2%) | .4687 |
| Characteristic . | CR/PR patients (n = 42) . | PR-L patients (n = 17) . | P value* . |
|---|---|---|---|
| Median age (range) | 66.0 (37-82) | 67.0 (55-75) | |
| Male gender | 30 (71.4%) | 13 (76.5%) | .759 |
| Median baseline WBC (range, 109/L) | 12.3 (1.7-308.1) | 31.6 (3.8-122.0) | .482 |
| Median peak WBC (range, 109/L) | 51.5 (5.2-619.1) | 156.3 (29.1-361.1) | .006 |
| Lymph node size ≥5 cm | 24 (57.1%) | 6 (35.3%) | .158 |
| Lymph node size ≥10 cm | 7 (16.7%) | 2 (11.8%) | 1.000 |
| Rai stage at baseline | |||
| Intermediate (I/II) | 11 (26.2%) | 6 (35.3%) | .753 |
| High (III/IV) | 28 (66.7%) | 11 (64.7) | |
| Unknown | 3 (7.2%) | 0 | |
| Fluorescence in situ hybridization abnormalities | |||
| Trisomy 12 | 6 (14.3) | 0 | .175 |
| Del13q | 15 (35.7%) | 12 (70.6%) | .010 |
| Del11q | 15 (35.7%) | 7 (41.2%) | .444 |
| Del17p | 13 (31.0%) | 3 (17.6%) | .364 |
| IGHV mutated | 5 (11.9%) | 7 (41.2%) | .015 |
| Zap-70 methylated at CpG3 | 11 (26.2%) | 7 (41.2%) | .4687 |
WBC, white blood cell.
For WBC at baseline and peak, the Wilcoxon 2-sample test with normal approximation was used; for all categorical variables, Fisher’s exact test was used. In performing Fisher’s exact test, missing or unknown observations were excluded and Rai stages were combined to intermediate (I/II) and high (III/IV). Bold text indicates statistically significant values.